173 related articles for article (PubMed ID: 34735828)
1. Diffusion kurtosis imaging combined with dynamic susceptibility contrast-enhanced MRI in differentiating high-grade glioma recurrence from pseudoprogression.
Shi W; Qu C; Wang X; Liang X; Tan Y; Zhang H
Eur J Radiol; 2021 Nov; 144():109941. PubMed ID: 34735828
[TBL] [Abstract][Full Text] [Related]
2. Differentiating high-grade glioma recurrence from pseudoprogression: Comparing diffusion kurtosis imaging and diffusion tensor imaging.
Wu XF; Liang X; Wang XC; Qin JB; Zhang L; Tan Y; Zhang H
Eur J Radiol; 2021 Feb; 135():109445. PubMed ID: 33341429
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
[TBL] [Abstract][Full Text] [Related]
6. Integrating diffusion kurtosis imaging, dynamic susceptibility-weighted contrast-enhanced MRI, and short echo time chemical shift imaging for grading gliomas.
Van Cauter S; De Keyzer F; Sima DM; Sava AC; D'Arco F; Veraart J; Peeters RR; Leemans A; Van Gool S; Wilms G; Demaerel P; Van Huffel S; Sunaert S; Himmelreich U
Neuro Oncol; 2014 Jul; 16(7):1010-21. PubMed ID: 24470551
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic value of quantitative analysis of ASL, DSC-MRI and DKI in the grading of cerebral gliomas: a meta-analysis.
Luan J; Wu M; Wang X; Qiao L; Guo G; Zhang C
Radiat Oncol; 2020 Aug; 15(1):204. PubMed ID: 32831106
[TBL] [Abstract][Full Text] [Related]
8. Histogram analysis of diffusion kurtosis imaging derived maps may distinguish between low and high grade gliomas before surgery.
Qi XX; Shi DF; Ren SX; Zhang SY; Li L; Li QC; Guan LM
Eur Radiol; 2018 Apr; 28(4):1748-1755. PubMed ID: 29143940
[TBL] [Abstract][Full Text] [Related]
9. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
[TBL] [Abstract][Full Text] [Related]
10. Noninvasively Evaluating the Grading of Glioma by Multiparametric Magnetic Resonance Imaging.
Zhang L; Yang LQ; Wen L; Lv SQ; Hu JH; Li QR; Xu JP; Xu RF; Zhang D
Acad Radiol; 2021 May; 28(5):e137-e146. PubMed ID: 32417035
[TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of diffuse glioma grade and proliferation activity by different diffusion-weighted-imaging models including diffusion kurtosis imaging (DKI) and mean apparent propagator (MAP) MRI.
Xie SH; Lang R; Li B; Zhao H; Wang P; He JL; Ma XY; Wu Q; Wang SY; Zhang HP; Gao Y; Wu JL
Neuroradiology; 2023 Jan; 65(1):55-64. PubMed ID: 35835879
[TBL] [Abstract][Full Text] [Related]
13. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma.
Nierobisch N; Ludovichetti R; Kadali K; Fierstra J; Hüllner M; Michels L; Achangwa NR; Alcaide-Leon P; Weller M; Kulcsar Z; Hainc N
Eur J Radiol; 2023 Oct; 167():111076. PubMed ID: 37666072
[TBL] [Abstract][Full Text] [Related]
15. Analysis of postprocessing steps for residue function dependent dynamic susceptibility contrast (DSC)-MRI biomarkers and their clinical impact on glioma grading for both 1.5 and 3T.
Bell LC; Stokes AM; Quarles CC
J Magn Reson Imaging; 2020 Feb; 51(2):547-553. PubMed ID: 31206948
[TBL] [Abstract][Full Text] [Related]
16. Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation.
Quan G; Zhang K; Liu Y; Ren JL; Huang D; Wang W; Yuan T
J Oncol; 2021; 2021():1696387. PubMed ID: 33628239
[TBL] [Abstract][Full Text] [Related]
17. Amide proton transfer imaging to discriminate between low- and high-grade gliomas: added value to apparent diffusion coefficient and relative cerebral blood volume.
Choi YS; Ahn SS; Lee SK; Chang JH; Kang SG; Kim SH; Zhou J
Eur Radiol; 2017 Aug; 27(8):3181-3189. PubMed ID: 28116517
[TBL] [Abstract][Full Text] [Related]
18. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI.
Sauwen N; Acou M; Van Cauter S; Sima DM; Veraart J; Maes F; Himmelreich U; Achten E; Van Huffel S
Neuroimage Clin; 2016; 12():753-764. PubMed ID: 27812502
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric MRI in differentiating solitary brain metastasis from high-grade glioma: diagnostic value of the combined use of diffusion-weighted imaging, dynamic susceptibility contrast imaging, and magnetic resonance spectroscopy parameters.
Aslan K; Gunbey HP; Tomak L; Incesu L
Neurol Neurochir Pol; 2019; 53(3):227-237. PubMed ID: 31180131
[TBL] [Abstract][Full Text] [Related]
20. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
